Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma

Sorafenib (SO) is a multi-kinase inhibitor that targets upstream signals in the MAPK pathway. Drug resistance and transient survival benefits are the main obstacles associated with SO treatment in Hepatocellular carcinoma (HCC) patients. Mebendazole (MBZ), an anthelmintic agent, has demonstrated act...

Descripción completa

Detalles Bibliográficos
Autores principales: Younis, Nancy S., Ghanim, Amal M. H., Saber, Sameh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911098/
https://www.ncbi.nlm.nih.gov/pubmed/31836811
http://dx.doi.org/10.1038/s41598-019-55666-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911098/
https://www.ncbi.nlm.nih.gov/pubmed/31836811
http://dx.doi.org/10.1038/s41598-019-55666-x

Ejemplares similares